← Back to Search

Diagnostic Imaging

Metabolic MRI for Brain Tumor

Phase < 1

Recruiting

Led By Benjamin M Ellingson

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade), 10 IDH mutant and 10 IDH wild type gliomas, clinically indicated for resective surgery or biopsy, age 18+, tumor size > 1x1x1 cm (measurable)

AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease, age 18+

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new MRI sequence to better detect and diagnose brain tumors.

Who is the study for?

This trial is for adults over 18 with newly diagnosed or recurrent glioma, a type of brain tumor. Healthy volunteers are also needed for part of the study. Participants must be able to safely undergo MRI scans and have tumors measurable at least 1cm in size. Those receiving immunotherapy for recurrent glioma can join too.Check my eligibility

What is being tested?

The trial is testing a new multinuclear metabolic MRI sequence designed to improve early detection, diagnosis, prognosis, and treatment planning in brain cancer patients. It involves biospecimen collection and diagnostic imaging using this novel technology.See study design

What are the potential side effects?

Since the interventions involve non-invasive imaging techniques like MRI rather than drugs or surgery, side effects are minimal but may include discomfort from lying still during the scan or reactions to contrast agents if used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older with a suspected or confirmed glioma, indicated for surgery, and my tumor is larger than 1cm³.

Select...

I am over 18 and do not have any brain tumors or neurological diseases.

Select...

I am 18 or older with recurrent glioma and am in an immunotherapy trial or need immunotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

NHE1 expression

Total sodium concentration

Tumor metabolism

Trial Design

1Treatment groups

Experimental Treatment

Group I: Basic science (MRI, metabolic imaging, tissue collection)Experimental Treatment3 Interventions

AIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis. AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biospecimen Collection

2004

Completed Phase 2

~1700

Magnetic Resonance Imaging

2017

Completed Phase 3

~1190

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED

865 Previous Clinical Trials

327,639 Total Patients Enrolled

Jonsson Comprehensive Cancer CenterLead Sponsor

361 Previous Clinical Trials

27,752 Total Patients Enrolled

Benjamin M EllingsonPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center

2 Previous Clinical Trials

58 Total Patients Enrolled

Media Library

Simultaneous Multinuclear Metabolic MRI (Diagnostic Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT05045027 — Phase < 1

Brain Tumor Research Study Groups: Basic science (MRI, metabolic imaging, tissue collection)

Brain Tumor Clinical Trial 2023: Simultaneous Multinuclear Metabolic MRI Highlights & Side Effects. Trial Name: NCT05045027 — Phase < 1

Simultaneous Multinuclear Metabolic MRI (Diagnostic Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05045027 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants accepted for this experiment?

"Affirmative. Clinicaltrials.gov data suggests that this medical research, which was initially posted on September 1st 2021, is actively searching for participants. The trial is aiming to enlist 60 individuals from a single site."

Answered by AI

To what extent is the subject pool participating in this clinical experiment?

"Affirmative. According to clinicaltrials.gov, this research is still taking on participants and was first posted on September 1st 2021 before being updated most recently on the 27th of September 2022. The study requires 60 individuals from a single medical centre for participation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

2021. "Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05045027.

All > Glioma